Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -6% Improvement Relative Risk Ventilation 50% ICU admission 49% Aspirin for COVID-19  Gogtay et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 125 patients in the USA (March - April 2020) Lower ventilation (p=0.16) and ICU admission (p=0.41), not sig. c19early.org Gogtay et al., World J. Critical Care .., Mar 2022 Favors aspirin Favors control

Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia

Gogtay et al., World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.000061 from 71 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Retrospective 125 COVID+ hospitalized patients in the USA, showing no significant differences with aspirin prophylaxis.
risk of death, 5.9% higher, RR 1.06, p = 0.87, treatment 12 of 38 (31.6%), control 21 of 87 (24.1%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 49.8% lower, RR 0.50, p = 0.16, treatment 5 of 38 (13.2%), control 21 of 87 (24.1%), NNT 9.1, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of ICU admission, 49.2% lower, RR 0.51, p = 0.41, treatment 9 of 38 (23.7%), control 38 of 87 (43.7%), NNT 5.0, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gogtay et al., 9 Mar 2022, retrospective, USA, peer-reviewed, 4 authors, study period March 2020 - April 2020. Contact: drgogtay@gmail.com.
This PaperAspirinAll
Retrospective analysis of aspirin's role in the severity of COVID-19 pneumonia
MD, Doctor, Maya Gogtay, Yuvaraj Singh, Asha Bullappa, Jeffrey Scott
World Journal of Critical Care Medicine, doi:10.5492/wjccm.v11.i2.92
The primary aim of the World Journal of Critical Care Medicine (WJCCM, World J Crit Care Med) is to provide scholars and readers from various fields of critical care medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJCCM mainly publishes articles reporting research results and findings obtained in the field of critical care medicine and covering a wide range of topics including acute kidney failure, acute respiratory distress syndrome and mechanical ventilation, application of bronchofiberscopy in critically ill patients, cardiopulmonary cerebral resuscitation, coagulant dysfunction, continuous renal replacement therapy, fluid resuscitation and tissue perfusion, hemodynamic monitoring and circulatory support, ICU management and treatment control, sedation and analgesia, severe infection, etc.
conflicting findings, the present study was designed to evaluate the impact of daily aspirin intake prior to hospitalization on the rate of COVID-19 positive patients' progression to the ICU. Research motivation With the never ending COVID-19 pandemic, it is imperative we find ways to keep patients out of the ICU. We have learnt that COVID-19 illness has major thrombotic and inflammatory effects. Aspirin would seem like an ideal choice to curb these effects. With this in mind, we conducted our study. But surprisingly we found that aspirin has no beneficial effects when it comes to preventing severe COVID-19 illness like ICU admissions. We postulate that patients taking aspirin were also older and had significant comorbidities, putting them at high risk for severe COVID-19. Furthermore, this study was carried out back when the most effective treatment modalities like steroids and remdesivir were not used. Hence, we conclude that aspirin's antiviral, anti-inflammatory and anti-thrombotic properties may not be strong enough to combat the COVID-19 illness. Research objectives Present study was designed to evaluate the impact of daily aspirin intake prior to hospitalization on the rate of COVID-19 positive patients' progression to the ICU. Research methods The idea of using the below methods were modeled after the study by Chow et al and the recovery trial on Aspirin in patients admitted to the hospital with COVID-19. Research methods adopted were the following: (1)..
References
Abdelwahab, Shaltout, Ahmed, Fouad, Merrell et al., Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study, Clin Drug Investig, doi:10.1007/s40261-021-01061-2
Aly, Ibrahim, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?, Med Hypotheses, doi:10.1016/j.mehy.2020.109975
Barnes, Burnett, Allen, Blumenstein, Clark et al., Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, J Thromb Thrombolysis, doi:10.1007/s11239-020-02138-z
Bianconi, Violi, Fallarino, Pignatelli, Sahebkar et al., Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?, Drugs, doi:10.1007/s40265-020-01365-1
Chow, Khanna, Kethireddy, Yamane, Levine et al., None
Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Ther Adv Respir Dis, doi:10.1177/1753466620937175
Lim, Pranata, Huang, Yonas, Soeroto et al., Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis, Can J Kidney Health Dis, doi:10.1177/2054358120938573
Nishiga, Wang, Han, Lewis, Wu, COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives, Nat Rev Cardiol, doi:10.1038/s41569-020-0413-9
Ornelas, Zacharias-Millward, Menter, Davis, Lichtenberger et al., Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention, Cancer Metastasis Rev, doi:10.1007/s10555-017-9675-z
Porfidia, Pola, Venous thromboembolism in COVID-19 patients, J Thromb Haemost, doi:10.1111/jth.14842
Pranata, Lim, Yonas, Huang, Nasution et al., Thrombocytopenia as a prognostic marker in COVID-19 patients: diagnostic test accuracy meta-analysis, Epidemiol Infect, doi:10.1017/S0950268821000236
Russell, Moss, Rigg, Van Hemelrijck, COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?, Ecancermedicalscience, doi:10.3332/ecancer.2020.1023
Wang, Wang, Chen, Qin, Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures, J Med Virol, doi:10.1002/jmv.25748
Wichmann, Sperhake, Lütgehetmann, Steurer, Edler et al., Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study, Ann Intern Med, doi:10.7326/M20-2003
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit